|
CN1925855B
(zh)
|
2003-12-19 |
2010-06-16 |
普莱希科公司 |
开发Ret调节剂的化合物和方法
|
|
DE102004017438A1
(de)
*
|
2004-04-08 |
2005-11-03 |
Bayer Healthcare Ag |
Hetaryloxy-substituierte Phenylaminopyrimidine
|
|
US7459562B2
(en)
|
2004-04-23 |
2008-12-02 |
Bristol-Myers Squibb Company |
Monocyclic heterocycles as kinase inhibitors
|
|
TW200538453A
(en)
|
2004-04-26 |
2005-12-01 |
Bristol Myers Squibb Co |
Bicyclic heterocycles as kinase inhibitors
|
|
WO2005121125A1
(en)
*
|
2004-06-09 |
2005-12-22 |
Pfizer Inc. |
Ether-linked heteroaryl compounds
|
|
US7498342B2
(en)
|
2004-06-17 |
2009-03-03 |
Plexxikon, Inc. |
Compounds modulating c-kit activity
|
|
US7432373B2
(en)
|
2004-06-28 |
2008-10-07 |
Bristol-Meyers Squibb Company |
Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
|
|
US7439246B2
(en)
|
2004-06-28 |
2008-10-21 |
Bristol-Myers Squibb Company |
Fused heterocyclic kinase inhibitors
|
|
US7173031B2
(en)
*
|
2004-06-28 |
2007-02-06 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
|
US7846941B2
(en)
|
2005-05-17 |
2010-12-07 |
Plexxikon, Inc. |
Compounds modulating c-kit and c-fms activity and uses therefor
|
|
UA95244C2
(ru)
|
2005-06-22 |
2011-07-25 |
Плексикон, Инк. |
Соединения и способ модулирования активности киназ, и показания для их применения
|
|
US8211919B2
(en)
|
2005-09-02 |
2012-07-03 |
Astellas Pharma Inc. |
Amide derivatives as rock inhibitors
|
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
|
WO2008079909A1
(en)
|
2006-12-21 |
2008-07-03 |
Plexxikon, Inc. |
Pyrrolo [2,3-b] pyridines as kinase modulators
|
|
PE20121126A1
(es)
|
2006-12-21 |
2012-08-24 |
Plexxikon Inc |
Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
|
|
JP2010514695A
(ja)
|
2006-12-21 |
2010-05-06 |
プレキシコン，インコーポレーテッド |
キナーゼ調節のための化合物および方法およびそのための適応症
|
|
CL2007003874A1
(es)
*
|
2007-01-03 |
2008-05-16 |
Boehringer Ingelheim Int |
Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
|
|
WO2009012283A1
(en)
|
2007-07-17 |
2009-01-22 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
JP5693239B2
(ja)
|
2008-01-23 |
2015-04-01 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
４−ピリジノン化合物および癌についてのその使用
|
|
MY172424A
(en)
|
2009-04-03 |
2019-11-25 |
Hoffmann La Roche |
Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
|
|
US8765747B2
(en)
|
2009-06-12 |
2014-07-01 |
Dana-Farber Cancer Institute, Inc. |
Fused 2-aminothiazole compounds
|
|
US8329724B2
(en)
|
2009-08-03 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Process for the manufacture of pharmaceutically active compounds
|
|
CN106220623A
(zh)
|
2009-11-06 |
2016-12-14 |
普莱希科公司 |
用于激酶调节的化合物和方法及其适应症
|
|
WO2011090738A2
(en)
|
2009-12-29 |
2011-07-28 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
|
US8530444B2
(en)
*
|
2010-06-01 |
2013-09-10 |
Aposense Ltd. |
Pharmaceutical compounds
|
|
US9192680B2
(en)
|
2010-06-01 |
2015-11-24 |
Aposense Ltd. |
Pharmaceutical compounds
|
|
US9624213B2
(en)
|
2011-02-07 |
2017-04-18 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
AR085279A1
(es)
|
2011-02-21 |
2013-09-18 |
Plexxikon Inc |
Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
|
|
US9382239B2
(en)
|
2011-11-17 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-Jun-N-terminal kinase (JNK)
|
|
CN102603740B
(zh)
*
|
2012-03-01 |
2014-05-14 |
南京药石药物研发有限公司 |
4-硝基-7-氮杂吲哚的合成方法
|
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
|
TWI520962B
(zh)
*
|
2012-06-29 |
2016-02-11 |
|
As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
|
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
|
WO2015058126A1
(en)
|
2013-10-18 |
2015-04-23 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
|
EP3057956B1
(en)
|
2013-10-18 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
|
US9862688B2
(en)
|
2014-04-23 |
2018-01-09 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
|
JP6854762B2
(ja)
|
2014-12-23 |
2021-04-07 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
|
|
USRE50776E1
(en)
|
2015-03-27 |
2026-02-03 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
AU2016319125B2
(en)
|
2015-09-09 |
2021-04-08 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
EP4088719A1
(en)
|
2015-10-13 |
2022-11-16 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
|
|
US12048761B2
(en)
|
2015-10-13 |
2024-07-30 |
Inserm (Institut National De La Santé Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
|
|
GEP20207202B
(en)
*
|
2017-01-30 |
2020-12-25 |
Chiesi Farm Spa |
Tyrosine amide derivatives as rho-kinase inhibitors
|
|
EP3638670B1
(en)
|
2017-06-13 |
2021-07-21 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
|
|
WO2018228925A1
(en)
|
2017-06-13 |
2018-12-20 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
EP3638669A1
(en)
|
2017-06-13 |
2020-04-22 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
CA3070013A1
(en)
|
2017-07-18 |
2019-01-24 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
EP3810132A4
(en)
|
2018-06-25 |
2022-06-22 |
Dana-Farber Cancer Institute, Inc. |
TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
|
|
WO2020120257A1
(en)
|
2018-12-11 |
2020-06-18 |
Bayer Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
US12281126B2
(en)
|
2018-12-28 |
2025-04-22 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 and uses thereof
|
|
WO2021249913A1
(en)
|
2020-06-09 |
2021-12-16 |
Bayer Aktiengesellschaft |
2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
|
|
US20240174683A1
(en)
|
2021-02-05 |
2024-05-30 |
Bayer Aktiengesellschaft |
Map4k1 inhibitors
|
|
WO2025224050A1
(en)
|
2024-04-22 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Methods of treatment of patients suffering from hypomelanosis of ito
|